By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sonoma Pharma (Formerly Known As Oculus Innovative Sciences, Inc.) 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

Key Statistics

Ownership: Public

Web Site: Sonoma Pharma
Symbol: OCLS

Company News
Sonoma Pharma (OCLS) Reports Financial Results For Fiscal Third Quarter 2017 2/10/2017 8:59:07 AM
Sonoma Pharma (OCLS) Appoints Marc Umscheid As Chief Strategy And Marketing Officer 1/31/2017 8:10:25 AM
Sonoma Pharma (OCLS) Release: Company Announces Fiscal Third Quarter 2017 Financial Results And Conference Call 1/26/2017 7:40:37 AM
Oculus Innovative Sciences (OCLS) Announces Corporate Name Change To Sonoma Pharmaceuticals, Inc. And New NASDAQ Ticker Symbol To Better Align With Dermatology Focus 12/5/2016 8:43:22 AM
Oculus Innovative Sciences (OCLS) Reports Financial Results For Fiscal Second Quarter 2017 11/11/2016 10:42:36 AM
Oculus Innovative Sciences (OCLS) Sells Latin America Business To Invekra S.A.P.I. De C.V. For $19.5 Million In Cash 11/1/2016 10:36:21 AM
Oculus Innovative Sciences (OCLS) Launches Lasercyn Into U.S. Dermatology Market For Use Following Laser Procedures, Microdermabrasions And Chemical Peels 8/30/2016 8:08:01 AM
Oculus Innovative Sciences (OCLS) Wins FDA Nod for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms 8/24/2016 8:00:28 AM
Oculus Innovative Sciences (OCLS) Receives Australian Approvals To Market Sterile Microcyn-Based Antimicrobial Solutions And Hydrogel Dressings 8/11/2016 11:26:26 AM
Oculus Innovative Sciences (OCLS) Reports Financial Results For First Quarter Of Fiscal Year 2017 7/29/2016 8:31:15 AM